WO2002000227A3 - Use of lanthanum compounds for the treatment of bone diseases - Google Patents

Use of lanthanum compounds for the treatment of bone diseases Download PDF

Info

Publication number
WO2002000227A3
WO2002000227A3 PCT/GB2001/002836 GB0102836W WO0200227A3 WO 2002000227 A3 WO2002000227 A3 WO 2002000227A3 GB 0102836 W GB0102836 W GB 0102836W WO 0200227 A3 WO0200227 A3 WO 0200227A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
bone diseases
lanthanum compounds
bone disease
differentiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2001/002836
Other languages
French (fr)
Other versions
WO2002000227A8 (en
WO2002000227A2 (en
Inventor
Nigel Derek Atherton
Joseph Wilson Totten
Michael David Gaitonde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Holdings AG
Original Assignee
Shire Holdings AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE60137929T priority Critical patent/DE60137929D1/en
Priority to AU2001274341A priority patent/AU2001274341B2/en
Priority to DE20122679U priority patent/DE20122679U1/en
Priority to EP01940848A priority patent/EP1294384B1/en
Priority to JP2002505009A priority patent/JP2004501198A/en
Priority to AU7434101A priority patent/AU7434101A/en
Application filed by Shire Holdings AG filed Critical Shire Holdings AG
Priority to CA2415228A priority patent/CA2415228C/en
Publication of WO2002000227A2 publication Critical patent/WO2002000227A2/en
Publication of WO2002000227A3 publication Critical patent/WO2002000227A3/en
Anticipated expiration legal-status Critical
Publication of WO2002000227A8 publication Critical patent/WO2002000227A8/en
Priority to FI20060389U priority patent/FI7569U1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/06—Chelate

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a method for enhancing bone formation, inhibiting osteoclastic differentiation and/or activating osteoblastic differentiation whereby to manage, treat or achieve prophylayxis of bone disease which comprises administering to a human or animal subject suffering from, or susceptible to bone disease a therapeutically or prophylactically effective amount of a lanthanum compound.
PCT/GB2001/002836 2000-06-27 2001-06-26 Use of lanthanum compounds for the treatment of bone diseases Ceased WO2002000227A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA2415228A CA2415228C (en) 2000-06-27 2001-06-26 Treatment of bone diseases
AU2001274341A AU2001274341B2 (en) 2000-06-27 2001-06-26 Use of lanthanum compounds for the treatment of bone diseases
DE20122679U DE20122679U1 (en) 2000-06-27 2001-06-26 Use of lanthanum (III) compounds for enhancing bone formation, inhibiting osteoclastic differentiation and/or activating osteoblastic differentiation to treat bone disease such as osteoporosis
EP01940848A EP1294384B1 (en) 2000-06-27 2001-06-26 Use of lanthanum compounds for the treatment of bone diseases
JP2002505009A JP2004501198A (en) 2000-06-27 2001-06-26 Use of lanthanum compounds for the treatment of bone diseases
DE60137929T DE60137929D1 (en) 2000-06-27 2001-06-26 USE OF LANTHAN IN THE TREATMENT OF BONE DISEASES
AU7434101A AU7434101A (en) 2000-06-27 2001-06-26 Treatment of bone diseases
FI20060389U FI7569U1 (en) 2000-06-27 2006-09-22 Pharmaceutical composition to treat or prevent a disorder in bone formation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0015745.3 2000-06-27
GBGB0015745.3A GB0015745D0 (en) 2000-06-27 2000-06-27 Treatment of bone diseases

Publications (3)

Publication Number Publication Date
WO2002000227A2 WO2002000227A2 (en) 2002-01-03
WO2002000227A3 true WO2002000227A3 (en) 2002-08-29
WO2002000227A8 WO2002000227A8 (en) 2004-04-15

Family

ID=9894512

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/002836 Ceased WO2002000227A2 (en) 2000-06-27 2001-06-26 Use of lanthanum compounds for the treatment of bone diseases

Country Status (11)

Country Link
US (2) US7078059B2 (en)
EP (2) EP2052725A2 (en)
JP (1) JP2004501198A (en)
AT (2) ATE424837T1 (en)
AU (2) AU7434101A (en)
CA (1) CA2415228C (en)
DE (1) DE60137929D1 (en)
DK (1) DK200600250U4 (en)
FI (1) FI7569U1 (en)
GB (1) GB0015745D0 (en)
WO (1) WO2002000227A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100015246A1 (en) * 2000-06-27 2010-01-21 Shire International Licensing B.V. Combination of a lanthanum compound and bone enhancing agent for the treatment of bone diseases
US7858602B2 (en) * 2000-10-16 2010-12-28 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells
WO2003094933A2 (en) * 2002-05-08 2003-11-20 Shire Holding Ag Use of lanthanum for the treatment of hypercalcemia and bone metastasis
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
EP1647524A3 (en) * 2002-08-14 2006-09-13 Altair Nanomaterials Inc. Rare earth metal compounds, methods of making, and methods of using the same
US7220406B2 (en) * 2002-10-22 2007-05-22 Genzyme Corporation Method for promoting bone formation
PT1622630E (en) * 2003-05-07 2012-10-11 Osteologix As Strontium combinations for the prophylaxis/treatment of cartilage and/or bone conditions
US20060216358A1 (en) * 2003-05-07 2006-09-28 Christian Hansen Controlled release composition containing a strontium salt
PT1534305E (en) * 2003-05-07 2007-02-28 Osteologix As Treating cartilage / bone conditions with water-soluble strontium salts
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
DK2792363T3 (en) * 2003-08-26 2016-09-26 Shire Biopharmaceuticals Holdings Ireland Ltd PHARMACEUTICAL FORM, INCLUDING LANTHAN CONNECTIONS
MX2007001114A (en) * 2004-07-27 2007-07-11 Shire Pharmaceuticals Inc Method of treating hyperphosphataemia using lanthanum hydroxycarbonate.
US20060134225A1 (en) * 2004-10-15 2006-06-22 Moerck Rudi E Phosphate binder with reduced pill burden
EP1698233A1 (en) * 2005-03-01 2006-09-06 Bayer HealthCare AG Reduction of digestibility of phosphorus in animal nutrition
WO2007022445A2 (en) * 2005-08-17 2007-02-22 Altairnano, Inc. Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
CA2621264A1 (en) * 2005-09-06 2007-11-15 Zelos Therapeutics, Inc. Parathyroid hormone analogues and methods of use
US20110046059A1 (en) * 2005-09-06 2011-02-24 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
US20070259052A1 (en) * 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
WO2008148215A1 (en) * 2007-06-07 2008-12-11 Aubin Jane E Estrogen receptor-related receptor gamma (err gamma) in bone and cartilage formation and methods and compositions relating to same
GB0806801D0 (en) * 2008-04-15 2008-05-14 Immunodiagnostic Systems Ltd Substrate
AU2011252983C1 (en) 2010-05-12 2015-02-19 Unicycive Therapeutics, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
WO2011156583A1 (en) 2010-06-10 2011-12-15 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Isotopic biomarkers for rapid assessment of bone mineral balance in biomedical applications
JP5876476B2 (en) * 2010-06-11 2016-03-02 モリーコープ ミネラルズ エルエルシーＭｏｌｙｃｏｒｐ Ｍｉｎｅｒａｌｓ Ｌｌｃ Improvement of bioactive compounds from wastewater
US20160220639A1 (en) * 2013-09-11 2016-08-04 New York University Methods and compositions for treating bone diseases
MX370462B (en) 2014-03-07 2019-12-13 Secure Natural Resources Llc Cerium (iv) oxide with exceptional arsenic removal properties.
EP2932974A1 (en) * 2014-04-15 2015-10-21 Chemische Fabrik Budenheim KG Composition for prophylaxis and treatment of bone disorders
WO2025152053A1 (en) * 2024-01-17 2025-07-24 内蒙古医科大学 Use of soluble lanthanum in ameliorating arthritis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2493704A1 (en) * 1980-11-07 1982-05-14 Lemouel Jean Compsns. for dental caries and bone demineralisation - contg. an acid:resistant natural carbonate
US5342604A (en) * 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
US5714631A (en) * 1988-10-31 1998-02-03 The Dow Chemical Company Conjugates possessing ortho ligating functionality
US5902825A (en) * 1997-01-07 1999-05-11 Mitreoak, Ltd. Composition and method for the palliation of pain associated with diseases of the bone and bone joints

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869473A (en) * 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US5171583A (en) 1988-10-21 1992-12-15 The Regents Of The University Of California Treatment of osteoporosis using potassium bicarbonate
GB9506126D0 (en) 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
AU2002213483B2 (en) * 2000-10-13 2007-03-29 Abbott Laboratories A method of determining the initial dose of vitamin D compounds
AU2003272767A1 (en) * 2002-09-30 2004-04-23 Schering Corporation Use of tricyclic amides for the treatment of disorders of calcium homeostasis
DK2792363T3 (en) * 2003-08-26 2016-09-26 Shire Biopharmaceuticals Holdings Ireland Ltd PHARMACEUTICAL FORM, INCLUDING LANTHAN CONNECTIONS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2493704A1 (en) * 1980-11-07 1982-05-14 Lemouel Jean Compsns. for dental caries and bone demineralisation - contg. an acid:resistant natural carbonate
US5342604A (en) * 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
US5714631A (en) * 1988-10-31 1998-02-03 The Dow Chemical Company Conjugates possessing ortho ligating functionality
US5902825A (en) * 1997-01-07 1999-05-11 Mitreoak, Ltd. Composition and method for the palliation of pain associated with diseases of the bone and bone joints

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DOTY S.B.: "Morphological evidence of gap junctions between bone cells.", CALCIFIED TISSUE INTERNATIONAL, (1981) 33/5 (509-512). CODEN: CATRBZ, XP000912197 *
FERNANDEZ-GAVARRON, FEDERICO ET AL: "Incorporation of 140- lanthanum into bones, teeth and hydroxyapatite", BONE MINER. (1988), 3(4), 283-91, XP000912072 *
HARRIS A F ET AL: "The effect of lanthanum chloride and related compounds on calcification.", ARCHIVES INTERNATIONALES DE PHARMACODYNAMIE ET DE THERAPIE, (1970 AUG) 18 (2) 269-78., XP000912133 *
SHANKAR, VIJAI S. ET AL: "Activation and inactivation of the osteoclast calcium receptor by the trivalent cation, lanthanum (3+)", BIOCHEM. BIOPHYS. RES. COMMUN. (1992), 187(2), 907-12, XP000938869 *
WASSERMAN, R. H. ET AL: "Effect of vitamin D3 on lanthanum absorption. Suggestive evidence for a shunt path", CALCIUM METAB., BONE METAB. BONE DIS., [PROC. EUR. SYMP. CALCIF. TISSUES] 10TH (1975), MEETING DATE 1973, 87-90. EDITOR(S): KUHLENCORDT, FRIEDRICH KRUSE, HANS-PETER. PUBLISHER: SPRINGER, NEW YORK, N. Y., XP008002113 *

Also Published As

Publication number Publication date
AT9687U1 (en) 2008-02-15
EP1294384B1 (en) 2009-03-11
US7078059B2 (en) 2006-07-18
FIU20060389U0 (en) 2006-09-22
US20070048390A1 (en) 2007-03-01
CA2415228A1 (en) 2002-01-03
DK200600250U1 (en) 2007-01-12
EP2052725A2 (en) 2009-04-29
AU7434101A (en) 2002-01-08
GB0015745D0 (en) 2000-08-16
WO2002000227A8 (en) 2004-04-15
FI7569U1 (en) 2007-07-17
ATE424837T1 (en) 2009-03-15
CA2415228C (en) 2011-09-06
WO2002000227A2 (en) 2002-01-03
EP1294384A2 (en) 2003-03-26
US20020051822A1 (en) 2002-05-02
AU2001274341B2 (en) 2006-10-19
DE60137929D1 (en) 2009-04-23
DK200600250U4 (en) 2008-09-12
JP2004501198A (en) 2004-01-15

Similar Documents

Publication Publication Date Title
WO2002000227A8 (en) Use of lanthanum compounds for the treatment of bone diseases
AU5977401A (en) Delivery devices for treatment of vascular disease
MY127290A (en) New use of flibanserin
IL153442A0 (en) Treatment of central nervous system diseases by antibodies against glatiramer acetate
WO2001001973A3 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
WO2004056307A3 (en) Disease treatment via antimicrobial peptide inhibitors
DE60027209D1 (en) MEDICAMENT CONTAINS HYDROXYAPATITE FOR THE TREATMENT OF BONE WEBBLE DISEASES
DE50013843D1 (en) MEDICAMENT FOR THE TREATMENT OF DARMER DISEASES
IL164822A0 (en) Growth factor delivery system for the healing of wounds and the prevention and disease
AU2002322263A1 (en) Eglin c based drugs for treatment of disease
MXPA02006511A (en) Complex comprising ocif and polysaccharide.
WO2004092378A3 (en) Method for treatment of cancerous angiogenic disorders
DE60141759D1 (en) METHOD OF TREATING THE CENTRAL NERVOUS SYSTEM BY APPLICATION OF STRUCTURAL ANALOGUES OF IGF
EP1330251A4 (en) Combination therapy for the treatment of estrogen-sensitive disease
WO2000059940A3 (en) Platelet-derived growth factor related gene and protein
WO2008057599A3 (en) Methods for the treatment of abeta related disorders and compositions therefor
DE60306503D1 (en) STATIN THERAPY FOR IMPROVING THE MAINTENANCE OF COGNITIVE FUNCTION
WO2005000406A3 (en) Treatment of amyloid- and epileptogenesis-associated diseases
EP1614428A4 (en) MEDICAMENT FOR THE PREVENTION OR TREATMENT OF ANGIOGENIC OCULAR DISEASES
AU2900100A (en) Methods for inhibiting cathepsin k activity for the treatment of diseases related to bone loss
WO2003011309A3 (en) Pharmaceutical composition for treating hypercholesterolaemia
WO2002089848A3 (en) Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes
WO2003000269A3 (en) Novel use for pde 10a inhibitors
WO2002072098A8 (en) Method of treatment
HK1080369A1 (en) Epothilone derivatives for the treatment of multiple myeloma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2415228

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001274341

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 505009

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001940848

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001940848

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 01/2002 DUE TO A TECHNICAL PROBLEMAT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING UNDER (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION